Gingerenone A (10-50 mg/kg, orally, once a day, 15 weeks) reduces the increase in fat mass induced by a high-fat diet in mice by decreasing the size of fat cells, thereby inhibiting obesity and inflammation in adipose tissue[2].
Gingerenone A (5-20 mg/kg, orally, once a day, 7 days) can alleviate ferroptosis in the SLI of DSS-induced colitis mice, and its protective effect is associated with the activation of the Nrf2-Gpx4 signaling pathway[4].
| Animal Model: | HFD mice[2] |
| Dosage: | 10, 50 mg/kg; daily; 15 weeks |
| Administration: | Oral |
| Result: | Reduced fat gain without significantly affecting caloric intake, reduced visceral fat mass, and made fat cells smaller. |
| Animal Model: | Mice induced by DSS[6] |
| Dosage: | 5, 20 mg/kg; daily; 7 days |
| Administration: | Oral |
| Result: | Alleviated DSS-induced liver pathological damage, liver parameters and cytokine levels, increased antioxidant enzyme activities, alleviated ferroptosis, upregulated GPX4 expression, and activated Nrf2. |
